DK2435567T3 - Cdc45l-peptider og vacciner, der indbefatter disse - Google Patents
Cdc45l-peptider og vacciner, der indbefatter disse Download PDFInfo
- Publication number
- DK2435567T3 DK2435567T3 DK10780256.3T DK10780256T DK2435567T3 DK 2435567 T3 DK2435567 T3 DK 2435567T3 DK 10780256 T DK10780256 T DK 10780256T DK 2435567 T3 DK2435567 T3 DK 2435567T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide
- cdc45l
- cancer
- peptides
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (16)
1. Isoleret peptid på mindre end 15 aminosyrer med cytotoksisk T-lymfocyt (CTL)-inducerbarhed, hvor peptidet er et immunologisk aktivt fragment af et polypeptid, der består af aminosyresekvensen ifølge SEQ ID NO: 18 eller et modificeret peptid deraf, og hvor peptidet omfatter en aminosyresekvens udvalgt fra gruppen, der består af: (a) SEQ ID NO: 2; og (b) SEQ ID NO: 2, hvori 1 eller 2 aminosyrer er substitueret.
2. Isoleret peptid ifølge krav 1, hvor peptidet har en eller begge af følgende egenskaber: (a) den anden aminosyre fra N-terminalen er eller er modificeret til at være en aminosyre udvalgt fra gruppen, der består af phenylalanin, tyrosin, metionin og tryptofan; og (b) den C-terminale aminosyre er eller er modificeret til at være en aminosyre udvalgt fra gruppen, der består af phenylalanin, leucin, isoleucin, tryptofan og metionin.
3. Isoleret peptid ifølge krav 1 eller 2, hvor peptidet er et nonapeptid eller dekapeptid.
4. Isoleret peptid ifølge krav 1 eller 2, hvor peptidet består af aminosyresekvensen udvalgt fra gruppen, der består af: (a) SEQ ID NO: 2; og (b) SEQ ID NO: 2, hvori 1 eller 2 aminosyrer er substitueret.
5. Isoleret polynukleotid, der koder for peptidet ifølge et hvilket som helst af kravene 1 til 4.
6. Sammensætning til inducering af CTL, hvilken sammensætning omfatter et eller flere af peptiderne, der er anført i et hvilket som helst af kravene 1 til 4, eller et eller flere af polynukleotiderne, der er anført i krav 5. 1 1 Farmaceutisk sammensætning til behandling og/eller profylakse af cancer og/eller forebyggelse af postoperativt recidiv deraf, hvilken farmaceutiske sammensætning omfatter et eller flere af peptiderne, der er anført i et hvilket som helst af kravene 1 til 4 eller et eller flere af polynukleotiderne ifølge krav 5.
8. Farmaceutisk sammensætning ifølge krav 7, som er formuleret til administration til et individ, hvis HLA-antigen er HLA-A24.
9. In vitro- eller ex vivo-fremgangsmåde til inducering af en antigenpræsenterende celle (APC) med CTL-inducerbarhed, hvilken fremgangsmåde omfatter et trin udvalgt fra gruppen, der består af: (a) etablering af kontakt mellem en APC og peptidet ifølge et hvilket som helst af kravene 1 til 4 in vitro eller ex vivo og (b) indførelse af et polynukleotid, der koder for peptidet ifølge et hvilket som helst af kravene 1 til 4 i en APC in vitro eller ex vivo.
10. In vitro- eller ex vivo-fremgangsmåde til inducering af CTL, hvilken fremgangsmåde omfatter et trin udvalgt fra gruppen, der består af: (a) dyrkning af en CD8-positiv T-celle sammen med en APC, der på dens overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge et hvilket som helst af kravene 1 til 4; (b) dyrkning af en CD8-positiv T-celle sammen med et exosom, der på dets overflade præsenterer et kompleks af et HLA-antigen og et peptid ifølge et hvilket som helst af kravene 1 til 4; og (c) indførelse af et polynukleotid, der koder for et T-cellereceptor (TCR)-subunitpolypeptid, der er i stand til at binde til peptidet ifølge et hvilket som helst af kravene 1 til 4, i en T-celle. 1 2 3 1 Isoleret APC, der på dens overflade præsenterer et 2 kompleks af et HLA-antigen og peptidet ifølge et hvilket som 3 helst af kravene 1 til 4.
12. APC ifølge krav 11, der er induceret ved hjælp af fremgangsmåden ifølge krav 9.
13. Isoleret CTL, der er rettet mod peptidet ifølge et hvilket som helst af kravene 1 til 4.
14. CTL ifølge krav 13, der er induceret ved hjælp af fremgangsmåden ifølge krav 10.
15. Sammensætning til anvendelse i en fremgangsmåde til inducering af et immunrespons mod cancer i et individ, hvilken sammensætning omfatter et eller flere peptider ifølge et hvilket som helst af kravene 1 til 4 eller et eller flere polynukleotider, der koder for peptidet.
16. Antistof eller fragment deraf mod peptidet, der består af aminosyresekvensen ifølge SEQ ID NO: 2.
17. Vektor, der omfatter en nukleotidsekvens, der koder for peptidet ifølge et hvilket som helst af kravene 1 til 4.
18. Værtscelle, der er transformeret eller transficeret med en ekspressionsvektor ifølge krav 17. 1 1 Diagnostisk kit, der omfatter peptidet ifølge et hvilket som helst af kravene 1 til 4, polynukleotidet ifølge krav 5 eller antistoffet ifølge krav 16.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21713309P | 2009-05-26 | 2009-05-26 | |
| PCT/JP2010/003488 WO2010137295A1 (en) | 2009-05-26 | 2010-05-25 | Cdc45l peptides and vaccines including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2435567T3 true DK2435567T3 (da) | 2017-07-24 |
Family
ID=43222423
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17163532.9T DK3208334T3 (da) | 2009-05-26 | 2010-05-25 | Cdc45l-peptider og vacciner, der indbefatter disse |
| DK10780256.3T DK2435567T3 (da) | 2009-05-26 | 2010-05-25 | Cdc45l-peptider og vacciner, der indbefatter disse |
| DK19175920.8T DK3556857T3 (da) | 2009-05-26 | 2010-05-25 | Cdc45l-peptider og vacciner, der indeholder disse |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17163532.9T DK3208334T3 (da) | 2009-05-26 | 2010-05-25 | Cdc45l-peptider og vacciner, der indbefatter disse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19175920.8T DK3556857T3 (da) | 2009-05-26 | 2010-05-25 | Cdc45l-peptider og vacciner, der indeholder disse |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8586547B2 (da) |
| EP (4) | EP3556857B1 (da) |
| JP (1) | JP5903697B2 (da) |
| KR (1) | KR101765452B1 (da) |
| CN (3) | CN102459589B (da) |
| AU (1) | AU2010253356B2 (da) |
| BR (1) | BRPI1010666B1 (da) |
| CA (3) | CA3011607C (da) |
| DK (3) | DK3208334T3 (da) |
| ES (3) | ES2631952T3 (da) |
| IL (1) | IL216211A (da) |
| MX (1) | MX2011012619A (da) |
| RU (1) | RU2562160C2 (da) |
| SG (1) | SG176058A1 (da) |
| TW (1) | TWI507204B (da) |
| WO (1) | WO2010137295A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104066746B (zh) * | 2011-10-28 | 2017-12-05 | 肿瘤疗法科学股份有限公司 | Topk肽及包含它们的疫苗 |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| PL4029494T3 (pl) | 2017-01-25 | 2026-03-23 | Ose Immunotherapeutics | Sposób wytwarzania stabilnej emulsji do dostarczania peptydów |
| SG11202002520UA (en) | 2017-09-19 | 2020-04-29 | Univ British Columbia | Anti-hla-a2 antibodies and methods of using the same |
| EP3684822A4 (en) | 2017-09-20 | 2021-06-16 | The University of British Columbia | NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| WO1997005900A1 (en) | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
| US20030068623A1 (en) * | 1997-06-16 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| JP4413429B2 (ja) | 1998-06-25 | 2010-02-10 | 株式会社グリーンペプタイド | サイクロフィリンｂ由来の腫瘍抗原ペプチド |
| DK2336167T3 (da) | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| DE60327786D1 (de) * | 2002-09-12 | 2009-07-09 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| JP4370409B2 (ja) | 2005-06-22 | 2009-11-25 | 国立大学法人東北大学 | がんの予後予測方法 |
| EP2295570A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| EP2311985A1 (en) * | 2005-07-27 | 2011-04-20 | Oncotherapy Science, Inc. | Sirna for treating esophageal cancer |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| AU2007259667B2 (en) * | 2006-06-16 | 2012-06-14 | Oncotherapy Science, Inc. | SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same |
| US8470534B2 (en) | 2006-12-01 | 2013-06-25 | Erik S. Knudsen | Methods of predicting resistance or sensitivity to therapies for cancer |
| TWI441648B (zh) * | 2007-01-03 | 2014-06-21 | Oncotherapy Science Inc | Ｆｏｘｐ３胜肽疫苗 |
-
2010
- 2010-05-21 TW TW099116260A patent/TWI507204B/zh not_active IP Right Cessation
- 2010-05-25 CN CN201080033325XA patent/CN102459589B/zh not_active Expired - Fee Related
- 2010-05-25 SG SG2011083813A patent/SG176058A1/en unknown
- 2010-05-25 EP EP19175920.8A patent/EP3556857B1/en active Active
- 2010-05-25 ES ES10780256.3T patent/ES2631952T3/es active Active
- 2010-05-25 DK DK17163532.9T patent/DK3208334T3/da active
- 2010-05-25 WO PCT/JP2010/003488 patent/WO2010137295A1/en not_active Ceased
- 2010-05-25 DK DK10780256.3T patent/DK2435567T3/da active
- 2010-05-25 EP EP10780256.3A patent/EP2435567B1/en not_active Not-in-force
- 2010-05-25 CA CA3011607A patent/CA3011607C/en active Active
- 2010-05-25 ES ES17163532T patent/ES2746334T3/es active Active
- 2010-05-25 BR BRPI1010666-9A patent/BRPI1010666B1/pt not_active IP Right Cessation
- 2010-05-25 AU AU2010253356A patent/AU2010253356B2/en not_active Ceased
- 2010-05-25 RU RU2011152975/10A patent/RU2562160C2/ru active
- 2010-05-25 EP EP21160385.7A patent/EP3868778A3/en not_active Withdrawn
- 2010-05-25 KR KR1020117030872A patent/KR101765452B1/ko not_active Expired - Fee Related
- 2010-05-25 CN CN201310610796.8A patent/CN103694315B/zh not_active Expired - Fee Related
- 2010-05-25 US US13/321,812 patent/US8586547B2/en not_active Expired - Fee Related
- 2010-05-25 DK DK19175920.8T patent/DK3556857T3/da active
- 2010-05-25 ES ES19175920T patent/ES2875950T3/es active Active
- 2010-05-25 CN CN201510386650.9A patent/CN105153279B/zh not_active Expired - Fee Related
- 2010-05-25 CA CA3167451A patent/CA3167451A1/en active Pending
- 2010-05-25 CA CA2762934A patent/CA2762934C/en active Active
- 2010-05-25 EP EP17163532.9A patent/EP3208334B1/en active Active
- 2010-05-25 MX MX2011012619A patent/MX2011012619A/es active IP Right Grant
- 2010-05-25 JP JP2011550339A patent/JP5903697B2/ja active Active
-
2011
- 2011-11-08 IL IL216211A patent/IL216211A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520659A (ja) | Ｎｅｉｌ３ペプチドおよびそれを含むワクチン | |
| RU2612905C2 (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| DK2435567T3 (da) | Cdc45l-peptider og vacciner, der indbefatter disse | |
| JP2015529629A (ja) | Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン | |
| US8530430B2 (en) | TTK peptides and vaccines including the same | |
| DK2646546T3 (da) | Tomm34-peptider og vacciner, der indeholder disse | |
| DK2553096T3 (da) | Ect2-peptider og vacciner, der indbefatter disse | |
| HK40057055A (en) | Cdc45l peptides and vaccines including the same | |
| HK1242735B (en) | Cdc45l peptides and vaccines including the same | |
| HK1166098A (en) | Cdc45l peptides and vaccines including the same | |
| HK1166098B (en) | Cdc45l peptides and vaccines including the same | |
| HK40015530A (en) | Cdc45l peptides and vaccines including the same | |
| HK40015530B (en) | Cdc45l peptides and vaccines including the same | |
| HK1242735A1 (en) | Cdc45l peptides and vaccines including the same | |
| HK1242735A (en) | Cdc45l peptides and vaccines including the same |